Medtechs Worry That Europe’s Biggest Killer Could Escape Their Grasp

EU Cardiovascular Community Urges More Resources And Focus On CVD

The European Alliance for Cardiovascular Health is three years old in September. Its remit to improve patient health has attracted strong support from stakeholders, but more investment and attention are required to ensure its momentum towards implementation is not lost. Experts at MedTech Forum 2024 explained what is at stake.

MedTech Europe
L-R: Alexander Olbrechts (MTF), Franz Weidinger, Jean-Luc Lemercier, Birgit Beger, Neil Johnson • Source: MedTech Europe

Cardiovascular disease experts at MedTech Forum 2024 were in agreement that Europe’s cardiovascular health needs have reached a crucial moment. The consensus was that the next four or five years may be pivotal in getting the EU to agree to implement a cardiovascular health (CVH) plan.

“We don’t want to have to wait 30 years until the next opportunity.” So said Birgit Beger, CEO of the...

More from Market Access

More from In Vivo

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.